M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot PharmaphorumSpero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R D.Immunology & InflammationRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) Pharmaphorum Spero has licensed rights to an anti-CD40L antibody developed by China’s Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R D. Immunology & Inflammation Read full story Post navigation Previous: AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5BNext: Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026